These limitations may be outweighed by strengths of our study using liver biopsy (still the gold standard for fibrosis assessment) in a cohort of NAFLD patients from across Central Europe with information on genetic data on three important risk factors of NAFLD (PNPLA3, HSD17B13, and TM6SF2). Here, TM6SF2 is linked to metabolic dysfunction-associated steatotic liver disease.